Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand.
Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
Int J Mol Sci. 2022 Oct 6;23(19):11852. doi: 10.3390/ijms231911852.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex disease with variable severity. Patients experience frequent relapses where symptoms increase in severity, leaving them with a marked reduction in quality of life. Previous work has investigated molecular differences between ME/CFS patients and healthy controls, but not the dynamic changes specific to each individual patient. We applied precision medicine here to map genomic changes in two selected ME/CFS patients through a period that contained a relapse recovery cycle. DNA was isolated from two patients and a healthy age/gender matched control at regular intervals and captured the patient relapse in each case. Reduced representation DNA methylation sequencing profiles were obtained spanning the relapse recovery cycle. Both patients showed a significantly larger methylome variability (10-20-fold) through the period of sampling compared with the control. During the relapse, changes in the methylome profiles of the two patients were detected in regulatory-active regions of the genome that were associated, respectively, with 157 and 127 downstream genes, indicating disturbed metabolic, immune and inflammatory functions. Severe health relapses in the ME/CFS patients resulted in functionally important changes in their DNA methylomes that, while differing between the two patients, led to very similar compromised physiology. DNA methylation as a signature of disease variability in ongoing ME/CFS may have practical applications for strategies to decrease relapse frequency.
肌痛性脑脊髓炎/慢性疲劳综合征 (ME/CFS) 是一种病情复杂、轻重不一的疾病。患者会频繁出现病情加重的复发,生活质量显著下降。此前已有研究调查了 ME/CFS 患者与健康对照组之间的分子差异,但并未针对每位患者的具体动态变化进行研究。在这里,我们采用精准医疗方法,通过包含复发-缓解周期的一段时间,对两名选定的 ME/CFS 患者的基因组变化进行了研究。我们定期从两名患者和一名健康的年龄/性别匹配的对照者身上提取 DNA,并在每个病例中捕捉到患者的复发。我们获得了跨越复发-缓解周期的全基因组 DNA 甲基化测序图谱。与对照组相比,两名患者在整个采样期间的甲基组变异性显著更大(10-20 倍)。在复发期间,两名患者的甲基组谱发生了变化,这些变化发生在基因组的调控活性区域,分别与 157 个和 127 个下游基因相关,表明代谢、免疫和炎症功能受到干扰。ME/CFS 患者的严重健康复发导致其 DNA 甲基组发生了功能重要的变化,尽管两名患者之间存在差异,但导致了非常相似的生理功能受损。作为 ME/CFS 持续存在的疾病变异性的 DNA 甲基化特征,可能为降低复发频率的策略提供实际应用。